OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Letters is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
CD155 in tumor progression and targeted therapy	321
Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove data	284
Tumor-derived extracellular vesicle PD-1 promotes tumor immune evasion via disruption of peripheral T cell homeostasis	242
Phase separation-based screening identifies arsenic trioxide as the N-Myc-DNA interaction inhibitor for neuroblastoma therapy	238
Corrigendum to “Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells” [Canc. Lett. 573 (2023) 216364]	189
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers	152
NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis	151
LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation	146
Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models	145
Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing	141
Emerging neuroimmune mechanisms in cancer neuroscience	138
Modulating the gut microbiota: A novel perspective in colorectal cancer treatment	138
NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1β/Th1/IFN-γ in acute myeloid leukemia	125
Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: Advancing towards clinical application	122
Synergistic enhancement of radio-immunotherapy efficacy by IL-15 via macrophage activation and memory T cell response	121
Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway	119
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination	115
SF3B4-mediated alternative splicing in cancer development and progression	113
DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity	109
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LS	106
Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer	106
Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma	103
Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma	98
Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression	93
The past, present, and future of liver cancer research in China	93

Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia	90
Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring	89
SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC	89
PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca2+ flux	87
Inhibition of ribosomal RNA processing 15 Homolog (RRP15), which is overexpressed in hepatocellular carcinoma, suppresses tumour growth via induction of senescence and apoptosis	87
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma	86
Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries	85
Cooperation between IRTKS and deubiquitinase OTUD4 enhances the SETDB1-mediated H3K9 trimethylation that promotes tumor metastasis via suppressing E-cadherin expression	82
Expression of concern: “Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence” C	81
USP7-mediated ERβ stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma	81
Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor	81
A novel promoter-associated non-coding small RNA paGLI1 recruits FUS/P65 to transactivate GLI1 gene expression and promotes infiltrating glioma progression	80
Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer	80
IL-1α facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation	76
Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma	75
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds	74
Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells	74
Anaplastic thyroid cancer cells upregulate mitochondrial one-carbon metabolism to meet purine demand, eliciting a critical targetable vulnerability	74
Osteosarcoma exocytosis of soluble LGALS3BP mediates macrophages toward a tumoricidal phenotype	72
A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma	70
Editorial Board	70
Editorial Board	69
Editorial Board	68
Editorial Board	68
Editorial Board	67
Editorial Board	67
Editorial Board	66
NOS2 and COX2 predicts poor outcome in ER- breast cancer through immunosuppression. Novel Strategies to overcome immunosuppression	65
Potential Contribution of Ovarian Granulosa Cells to High-Grade Serous Ovarian Cancer Development	65
Lysine demethylase KDM1A/LSD1 inhibition enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer	63
Ethnic Diversity and Metabolic Variations in Ovarian Cancer Cells: Implications for Personalized Medicine Strategies	63
Oxysterol-Sterol Binding Proteins as Druggable Precision Targets in Ovarian Cancer	63
Precision cancer medicine in ovarian cancer	63
Aberrant Translational Mechanisms in Cancer Cells	62
Versatility of Exosomes for Cancer Therapy	61
Neuro-immune communication in breast cancer	61